PDL BioPharma (FRA:PDL) Institutional Ownership : 37.76% (As of May. 07, 2024)

View and export this data going back to 2006. Start your Free Trial

What is PDL BioPharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PDL BioPharma's institutional ownership is 37.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PDL BioPharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PDL BioPharma's Float Percentage Of Total Shares Outstanding is 96.68%.

PDL BioPharma Institutional Ownership Historical Data

The historical data trend for PDL BioPharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma Institutional Ownership Chart

PDL BioPharma Historical Data

The historical data trend for PDL BioPharma can be seen below:

	2020-03-31	2020-04-30	2020-05-31	2020-06-30	2020-07-31	2020-08-31	2020-09-30	2020-10-31	2020-11-30	2020-12-31
Institutional Ownership	42.66	44.17	44.45	47.67	47.99	46.11	44.55	44.64	44.73	37.76

PDL BioPharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

PDL BioPharma (FRA:PDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (FRA:PDL) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

932 Southwood Boulevard, Incline Villiage, NV, USA, 89451

Website

http://www.pdl.com

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

PDL BioPharma (FRA:PDL) Headlines

No Headlines